PMID- 24040460
OWN - NLM
STAT- MEDLINE
DCOM- 20140418
LR  - 20220331
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 6
IP  - 9
DP  - 2013
TI  - Primary ductal adenocarcinoma of the lacrimal sac: the first reported case.
PG  - 1929-34
AB  - Primary lacrimal sac tumor is extremely rare, and moreover, glandular tumor is 
      exceptional. Herein, we described the first documented case of primary ductal 
      adenocarcinoma of the lacrimal sac. A 79-year-old Japanese female presented with 
      persistent swelling of her left lower eyelid. Computed tomography demonstrated an 
      irregular-shaped tumor involving the left lacrimal sac, lower eyelid, sinonasal 
      tract, and internal side of the left orbit. Biopsy from the eyelid revealed a 
      poorly differentiated adenocarcinoma. Histopathological study of the resected 
      lacrimal sac tumor revealed an infiltrative neoplastic growth that was composed 
      of cribriform structures with comedonecrosis. The neoplastic cells had relatively 
      rich granular eosinophilic cytoplasm and large round to oval nuclei containing 
      conspicuous nucleoli. The left cervical lymph nodes had metastatic carcinoma. 
      Immunohistochemically, the neoplastic cells were diffusely positive for gross 
      cystic disease fluid protein-15 and androgen receptor. Moreover, mammalian target 
      of rapamycin (mTOR), 4E-BP1, and p4E-BP1 were expressed. According to these 
      results, an ultimate diagnosis of primary ductal adenocarcinoma of the lacrimal 
      sac was made. Only 9 cases of primary lacrimal sac adenocarcinoma have been 
      reported, and this is the first reported case of ductal adenocarcinoma of the 
      lacrimal sac. Ductal adenocarcinoma of the salivary gland shows an aggressive 
      clinical course, and the present case had multiple cervical lymph node 
      metastases. This report is the first to demonstrate that mTOR pathway proteins, 
      which are central proteins involved in carcinogenesis, are activated in ductal 
      adenocarcinoma. Therefore, mTOR inhibitor may be a potential candidate for 
      treatment of this highly aggressive carcinoma.
FAU - Ishida, Mitsuaki
AU  - Ishida M
AD  - Department of Clinical Laboratory Medicine and Division of Diagnostic Pathology, 
      Shiga University of Medical Science Shiga, Japan.
FAU - Iwai, Muneo
AU  - Iwai M
FAU - Yoshida, Keiko
AU  - Yoshida K
FAU - Kagotani, Akiko
AU  - Kagotani A
FAU - Kohzaki, Hideaki
AU  - Kohzaki H
FAU - Arikata, Masahiko
AU  - Arikata M
FAU - Shimizu, Takeshi
AU  - Shimizu T
FAU - Okabe, Hidetoshi
AU  - Okabe H
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20130815
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (EIF4EBP1 protein, human)
RN  - 0 (Phosphoproteins)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/analysis
MH  - Adenocarcinoma/chemistry/drug therapy/*secondary/surgery
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Biomarkers, Tumor/analysis
MH  - Biopsy
MH  - Cell Cycle Proteins
MH  - Eye Neoplasms/chemistry/drug therapy/*pathology/surgery
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Lacrimal Apparatus/*pathology/surgery
MH  - Lacrimal Apparatus Diseases/drug therapy/metabolism/*pathology/surgery
MH  - Lymphatic Metastasis
MH  - Molecular Targeted Therapy
MH  - Patient Selection
MH  - Phosphoproteins/analysis
MH  - Phosphorylation
MH  - Precision Medicine
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - TOR Serine-Threonine Kinases/analysis/antagonists & inhibitors
MH  - Tomography, X-Ray Computed
PMC - PMC3759502
OTO - NOTNLM
OT  - Ductal adenocarcinoma
OT  - lacrimal sac
OT  - mTOR pathway
EDAT- 2013/09/17 06:00
MHDA- 2014/04/20 06:00
PMCR- 2013/08/15
CRDT- 2013/09/17 06:00
PHST- 2013/07/04 00:00 [received]
PHST- 2013/07/21 00:00 [accepted]
PHST- 2013/09/17 06:00 [entrez]
PHST- 2013/09/17 06:00 [pubmed]
PHST- 2014/04/20 06:00 [medline]
PHST- 2013/08/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2013 Aug 15;6(9):1929-34. eCollection 2013.